Cancer
Precision covalent therapeutics for oncology targets.
The Next Generation of
Covalent Inhibitors
A biopharmaceutical company developing covalent inhibitors with novel chemistry and an AI-enabled chemoproteomic discovery platform with a mission to develope therapies for high-unmet medical needs.
Explore the scienceThyora Therapeutics aims to unlock disease-relevant proteins beyond the reach of conventional drug discovery and accelerate the development of next generation covalent therapies with greater precision and safer clinical profiles. Thyora expands the druggable proteome by using Covalogic™, in-house AI-enabled chemoproteomic platform, and novel covalent warheads to identify and engage previously inaccessible targets in cancer, neurological, and immune disorders.
Our Science
Targeted covalent modulation, by design
Covalent drugs bind their target and then, traditionally, form an irreversible chemical bond. Thyora's platform pairs novel warhead chemistry with the potential for greater potency, higher specificity, and lower systemic exposure.
Therapeutic Focus
Neuro
Addressing targets in neurological disorders.
Immune
Modulating drivers of immune disease.
Our People
Founders & Leadership
Advisors
Leads the Baran Laboratory at Scripps Research and co-founder of Vividion Therapeutics.
Former Chief Medical Officer at Pfizer, with 13 years leading oncology clinical development.
40 years leading drug discovery in cardiovascular, neuroscience, and viral therapeutics at BMS.
Partners
Advancing our science alongside leading institutions.
